Literature DB >> 30417253

A systematic review of factors affecting medication adherence among patients with osteoporosis.

C T Yeam1, S Chia1, H C C Tan1, Y H Kwan1,2, W Fong1,3,4, J J B Seng5.   

Abstract

The aim of this review was to identify factors that influence patients' adherence to anti-osteoporotic therapy. Factors identified that were associated with poorer medication adherence included polypharmacy, older age, and misconceptions about osteoporosis. Physicians need to be aware of these factors so as to optimize therapeutic outcomes for patients.
INTRODUCTION: To identify factors that influence patients' adherence to anti-osteoporotic therapy.
METHODS: A systematic review of literature was performed for articles published up till January 2018 using PubMed®, PsychINFO®, Embase®, and CINAHL®. Peer-reviewed articles which examined factors associated with anti-osteoporotic medication adherence were included. Classes of anti-osteoporotic therapy included bisphosphonates, parathyroid hormone-related analogue, denosumab, selective estrogen receptor modulators, estrogen/progestin therapy, calcitonin, and strontium ranelate. Meta-analyses, case reports/series, and other systematic reviews were excluded. Identified factors were classified using the World Health Organization's five dimensions of medication adherence (condition, patient, therapy, health-system, and socio-economic domains).
RESULTS: Of 2404 articles reviewed, 124 relevant articles were identified. The prevalence of medication adherence ranged from 12.9 to 95.4%. Twenty-four factors with 139 sub-factors were identified. Bisphosphonates were the most well-studied class of medication (n = 59, 48%). Condition-related factors that were associated with poorer medication adherence included polypharmacy, and history of falls was associated with higher medication adherence. Patient-related factors which were associated with poorer medication adherence included older age and misconceptions about osteoporosis while therapy-related factors included higher dosing frequency and medication side effects. Health system-based factors associated with poorer medication adherence included care under different medical specialties and lack of patient education. Socio-economic-related factors associated with poorer medication adherence included current smoker and lack of medical insurance coverage.
CONCLUSION: This review identified factors associated with poor medication adherence among osteoporotic patients. To optimize therapeutic outcomes for patients, clinicians need to be aware of the complexity of factors affecting medication adherence.

Entities:  

Keywords:  Anti-osteoporotic therapy; Bisphosphonates; Medication adherence; Osteoporosis; Patient compliance

Mesh:

Substances:

Year:  2018        PMID: 30417253     DOI: 10.1007/s00198-018-4759-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  135 in total

1.  Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule.

Authors:  D H Solomon; M A Brookhart; P Tsao; D Sundaresan; S E Andrade; K Mazor; R Yood
Journal:  Osteoporos Int       Date:  2010-09-29       Impact factor: 4.507

2.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.

Authors:  O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2006-09-16       Impact factor: 4.507

3.  Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.

Authors:  Fernie J A Penning-van Beest; Wim G Goettsch; Joëlle A Erkens; Ron M C Herings
Journal:  Clin Ther       Date:  2006-02       Impact factor: 3.393

4.  World-wide projections for hip fracture.

Authors:  B Gullberg; O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

Authors:  Jeffrey R Curtis; Huifeng Yun; Robert Matthews; Kenneth G Saag; Elizabeth Delzell
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

6.  The relationship of depression, anxiety and stress with low bone mineral density in post-menopausal women.

Authors:  Hany Burstein Erez; Aron Weller; Nachum Vaisman; Shulamith Kreitler
Journal:  Arch Osteoporos       Date:  2012       Impact factor: 2.617

7.  Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.

Authors:  Fernie J A Penning-van Beest; Joëlle A Erkens; M Olson; Ron M C Herings
Journal:  Curr Med Res Opin       Date:  2008-03-31       Impact factor: 2.580

8.  Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study.

Authors:  E M Clark; V C Gould; J H Tobias; R Horne
Journal:  Osteoporos Int       Date:  2015-08-19       Impact factor: 4.507

9.  Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.

Authors:  J D Ringe; G E Christodoulakos; D Mellström; H Petto; T Nickelsen; F Marín; I Pavo
Journal:  Curr Med Res Opin       Date:  2007-11       Impact factor: 2.580

10.  Long-term persistence with anti-osteoporosis drugs after fracture.

Authors:  C Klop; P M J Welsing; P J M Elders; J A Overbeek; P C Souverein; A M Burden; H A W van Onzenoort; H G M Leufkens; J W J Bijlsma; F de Vries
Journal:  Osteoporos Int       Date:  2015-03-31       Impact factor: 4.507

View more
  38 in total

Review 1.  Mobile health technologies for the management of rheumatic diseases: a systematic review of online stores in Brazil.

Authors:  Lucas Ogura Dantas; Cristiano Carvalho; Beatriz Cardinal Prando; Timothy E McAlindon; Paula Regina Mendes da Silva Serrão
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

2.  Patients' reasons for adhering to long-term alendronate therapy.

Authors:  J Pepe; C Cipriani; V Cecchetti; C Ferrara; G Della Grotta; V Danese; L Colangelo; S Minisola
Journal:  Osteoporos Int       Date:  2019-05-14       Impact factor: 4.507

3.  Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.

Authors:  Shinichi Nakatoh; Kenji Fujimori; Shigeyuki Ishii; Junko Tamaki; Nobukazu Okimoto; Sumito Ogawa; Masayuki Iki
Journal:  Arch Osteoporos       Date:  2021-09-13       Impact factor: 2.617

Review 4.  Advancing Artificial Intelligence in Health Settings Outside the Hospital and Clinic.

Authors:  Nakul Aggarwal; Mahnoor Ahmed; Sanjay Basu; John J Curtin; Barbara J Evans; Michael E Matheny; Shantanu Nundy; Mark P Sendak; Carmel Shachar; Rashmee U Shah; Sonoo Thadaney-Israni
Journal:  NAM Perspect       Date:  2020-11-30

5.  Effect of Electronic Prescribing Compared to Paper-Based (Handwritten) Prescribing on Primary Medication Adherence in an Outpatient Setting: A Systematic Review.

Authors:  David Aluga; Lawrence A Nnyanzi; Nicola King; Elvis A Okolie; Peter Raby
Journal:  Appl Clin Inform       Date:  2021-08-25       Impact factor: 2.762

6.  Identifying Patterns of Self-Reported Nonadherence Using Network Analysis in a Mixed German Cohort.

Authors:  Tino Prell; Gabriele Helga Franke; Melanie Jagla-Franke; Aline Schönenberg
Journal:  Patient Prefer Adherence       Date:  2022-05-03       Impact factor: 2.314

7.  Group medical consultation for osteoporosis: a prospective pilot study of patient experience in Canadian tertiary care.

Authors:  Emma O Billington; A Lynn Feasel; Jessica L VanDyke; Gregory A Kline
Journal:  Br J Gen Pract       Date:  2020-10-29       Impact factor: 5.386

8.  Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.

Authors:  G Adami; K G Saag; A S Mudano; E J Rahn; N C Wright; R C Outman; S L Greenspan; A Z LaCroix; J W Nieves; S L Silverman; E S Siris; N B Watts; M J Miller; S Ladores; J R Curtis; M I Danila
Journal:  Osteoporos Int       Date:  2020-02-04       Impact factor: 4.507

Review 9.  Optimal Dosing Regimen of Osteoporosis Drugs in Relation to Food Intake as the Key for the Enhancement of the Treatment Effectiveness-A Concise Literature Review.

Authors:  Agnieszka Wiesner; Mariusz Szuta; Agnieszka Galanty; Paweł Paśko
Journal:  Foods       Date:  2021-03-29

10.  Rates of Osteoporosis Management and Secondary Preventative Treatment After Primary Fragility Fractures.

Authors:  Bailey J Ross; Olivia C Lee; Mitchel B Harris; Thomas C Dowd; Felix H Savoie; William F Sherman
Journal:  JB JS Open Access       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.